-
2024-514954-63-00
9
2025-08-20
RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMAS
-
2024-515875-36-00
4
2025-08-18
Advanced biliary tract cancer (BTC)
-
2024-519052-82-00
4
2025-06-30
pleural mesothelioma
-
2024-517325-43-00
4
2025-06-19
multiple myeloma
-
2023-510294-34-00
5
2025-06-12
small lymphocytic lymphoma (SLL)
-
2024-513053-69-00
5
2025-04-16
Moderately to Severely Active Crohn's Disease (CD)
-
2023-508234-34-00
4
2025-01-27
Crohn's disease
-
2024-516372-14-00
11
2025-01-13
Asymptomatic Patients with frequent PVCs and normal LVEF
-
2024-517204-11-00
4
2024-08-30
microsatellite stable (MSS) colorectal cancer with liver-dominant meta
-
2024-516456-17-00
5
2024-05-07
patients admitted for an obstructive colon cancer
-
2022-502741-10-00
7
2024-01-26
Acute Leukemia with Mixed Lineage Leukemia (MLL)-rearrangement or Nucl
-
2022-502154-13-00
5
2023-10-27
Patients with well to moderately differentiated neuroendocrine tumors
-
2024-517288-22-01
6
2021-01-29
Lymphoma
-
2024-516103-16-00
4
2015-12-04
Acute Lymphoblastic Leukemia (ALL) in younger adults (18-59 years)
-
2024-511863-27-01
10
2024-12-06
Adult patients with ulcerative colitis diagnosed for at least 3 months
-
2024-516965-35-00
5
2024-10-28
Immune system disorders
-
2022-500430-29-00
5
2023-10-11
Myelodysplastic Syndrome (MDS)
-
2024-516168-27-00
5
2022-11-10
Adult patients with persistent or chronic immune thrombocytopenia
-
2023-503640-14-00
5
2022-02-17
Newly diagnosed Philadelphia-negative B-cell precursor Acute Lymphobla
-
2023-505807-21-00
5
2021-11-16
Relapsed/refractory follicular lymphoma
-
2024-517816-31-00
4
2021-03-19
For patients with advanced/metastatic gastric adenocarcinomas in
progr
-
2023-509358-72-00
5
2020-11-23
Diffuse large B-cell lymphoma
-
2024-514088-25-00
5
2019-10-07
Multiple Myeloma
-
2023-507405-34-00
5
2019-08-07
First-line patients with advanced biliary tract cancers (BTC)